Genetic Disorders – Development
Kidney International (2005) 67, 53–60; doi:10.1111/j.1523-1755.2005.00054.x
Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria
SERGEI V CHETYRKIN, DANIEL KIM, JOHN M BELMONT, JON I SCHEINMAN, BILLY G HUDSON and PAUL A VOZIYAN
Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas; Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas; and Division of Nephrology, Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas
Correspondence: Paul A. Voziyan, Division of Nephrology, Vanderbilt University Medical Center,S-3223 MCN, 1161 21st Avenue South, Nashville, TN 37232–2372. E-mail:paul.voziyan@vanderbilt.edu
Received 8 March 2004; Revised 28 May 2004; Re-revised 14 July 2004; Accepted 27 July 2004.
Abstract
Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria.
Background
Primary hyperoxaluria is a rare genetic disorder of glyoxylate metabolism that results in overproduction of oxalate. The disease is characterized by severe calcium oxalate nephrolithiasis and nephrocalcinosis, resulting in end-stage renal disease (ESRD) early in life. Most patients eventually require dialysis and kidney transplantation, usually in combination with the replacement of the liver. Reduction of urinary oxalate levels can efficiently decrease calcium oxalate depositions; yet, no treatment is available that targets oxalate biosynthesis. In previous in vitro studies, we demonstrated that pyridoxamine can trap reactive carbonyl compounds, including intermediates of oxalate biosynthesis.
Methods
The effect of PM on urinary oxalate excretion and kidney crystal formation was determined using the ethylene glycol rat model of hyperoxaluria. Animals were given 0.75% to 0.8% ethylene glycol in drinking water to establish and maintain hyperoxaluria. After 2 weeks, pyridoxamine treatment (180 mg/day/kg body weight) started and continued for an additional 2 weeks. Urinary creatinine, glycolate, oxalate, and calcium were measured along with the microscopic analysis of kidney tissues for the presence of calcium oxalate crystals.
Results
Pyridoxamine treatment resulted in significantly lower (by 
50%) levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals. This was accompanied by a significant reduction in calcium oxalate crystal formation in papillary and medullary areas of the kidney.
Conclusion
These results, coupled with favorable toxicity profiles of pyridoxamine in humans, show promise for therapeutic use of pyridoxamine in primary hyperoxaluria and other kidney stone diseases.
Keywords:
primary hyperoxaluria, kidney stone disease, pyridoxamine
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Oxalate in renal stone disease: the terminal metabolite that just won't go away
Nature Clinical Practice Nephrology Review (01 Jul 2008)
Oxalate in renal stone disease: the terminal metabolite that just won't go away
Nature Clinical Practice Nephrology Review (01 Jul 2008)
NEWS AND VIEWS
A key stone cop regulates oxalate homeostasis
Nature Genetics News and Views (01 Apr 2006)
RESEARCH
Kidney International Original Article
Relationship of protein intake to urinary oxalate and glycolate excretion
Kidney International Original Article
